Spike glycoprotein of SARS-CoV-2 (Omicron LP.8.1 variant) (S protein)

The spike glycoprotein of SARS-CoV-2 Omicron LP.8.1 variant is a large, trimeric class I viral fusion protein that protrudes from the viral envelope and is essential for viral entry into host cells. It mediates attachment by binding to the human angiotensin-converting enzyme 2 (ACE2) receptor through its receptor-binding domain (RBD) and facilitates membrane fusion, enabling the viral genome to enter the host cell[1][2][3][4][5]. The Omicron variant spike glycoprotein is notable for a large number of mutations, especially in the RBD and N-terminal domain, which enhance affinity for ACE2 and confer substantial resistance to many neutralizing antibodies, contributing to increased transmissibility and immune evasion[2]. The spike protein is the primary antigen targeted by COVID-19 vaccines and therapeutics. As the main immunodominant surface protein, it is highly glycosylated and conformationally dynamic, presenting a critical determinant of viral infectivity, host range, and tissue tropism[1][4][5].

Other names

Spike proteinS glycoproteinS proteinE2 (historic name)

Inhibition of spike–ACE2 interaction (prevents viral entry) Neutralization of virus by antibody binding to receptor-binding domain (RBD) Inhibition of conformational changes needed for membrane fusion Induction of immune response to spike protein (vaccination)